Noninvasive Bioreactance-Based Fluid Management Monitoring: A Review of Literature

Yatin Mehta1  Poonam Malhotra Kapoor2  Harish Mallapura Maheswarappa3  Gaurav Saxena4

1Medanta Institute of Critical Care and Anesthesiology, Medanta the Medicity, Gurugram, Haryana, India
2Department of Cardiac Anesthesiology, All India Institute of Medical Sciences, New Delhi, India
3Division of Critical Care Medicine, Critical Care and Pain, Department of Anaesthesiology, Tata Memorial Hospital, Mumbai, Maharashtra, India
4Medical Affairs Division, Baxter India Pvt Ltd, Gurugram, Haryana, India

Address for correspondence Gaurav Saxena, MBBS, Medical Affairs, Baxter India Pvt Ltd, Gurugram, Haryana, 122002, India (e-mail: Gaurav_saxena@baxter.com).

J Card Crit Care 2021;5:222–228.

Abstract

Body fluid balance is an independent predictor of mortality. For each liter of fluid over and above 5 L, risk-adjusted excess mortality is seen. Mortality increased by 2.3% for each 1 L of fluid and hospital costs increased by $999. Accordingly, most recent guidelines have endorsed dynamic modeling. Passive leg raising-induced increase of aortic blood flow ≥ 10% predicts fluid responsiveness with a sensitivity of 97% and a specificity of 94%. Thus, passive leg raising is often used as gold standard for validation of other procedures (though it’s usefulness to assess respiratory variation in vena cava is not conclusive). STARLING, a device based on bioreactance, works on phase shift or time delay while bioimpedance works on the amplitude of the thoracic impedance. Unlike bioimpedance, bioreactance is not affected by the size of the patient, thoracic fluids, or position of sensors. STARLING is equipped with four sensor pads. Each pad contains two sensors, the outer sensor is a transmitting electrode and the inner sensor is a receiving electrode. The STARLING monitor induces a 75-KHz AC current. It then measures the time delay/phase shift.

STARLING system, a bioreactance-based dynamic assessment system for fluid responsiveness, predicts it accurately, precisely, and noninvasively. It reduces invasive risks and is independently validated against pulmonary artery catheter. It is not affected by vasopressors or shock and has wide range of application.

Keywords
► bioreactance technology
► noninvasive fluid management
► STARLING

Introduction

Body fluid balance is an independent predictor of mortality. This is even more relevant in context of replenishment of fluid in conditions like shock—wherein less or more replenishment is equally hazardous. To depict it another way, the fluid-volume versus complication curve can be plotted in U-shape, with minima in the middle physiological region as shown in – Fig. 1.
At the same time, it is also known that in critical conditions, body fluids function through volume expansion and in addition to their actions as a matrix of various metabolic activities, they also act as the transport vehicle of nutrition, oxygenation, and excretion. Thereby, the replenished fluid is contextually a drug with low therapeutic index (analogous to antiarrhythmic drug which lead to arrhythmia in absence as well as when in excess) (Fig. 2).

The study was performed upon 23,513 severe sepsis/septic shock cases admitted to intensive care unit (ICU) and for each liter of fluid over and above 5 L, risk-adjusted excess mortality is seen. Mortality increased by 2.3% (95% confidence interval 2.0–2.5%, $p = 0.005$) for each 1 L of fluid and hospital costs increased by $999.2 Thus, the propensity model analysis looking at “mortality and fluid administration” using age and “acute conditions on admission” supports the hypothesis that fluid balance is an independent predictor of mortality.


Against the passive leg raising (PLR) and trending 500 mL fluid challenge, a minor bolus challenge of 300 was compared for assessing the fluid responsiveness—all the methods imply a play of Frank–Starling law. PLR-induced changes in cardiac output (CO) reliably predict the response of CO to volume expansion in adults with acute circulatory failure. PLR-induced increase of aortic blood flow $\geq 10\%$ predicts fluid responsiveness with a sensitivity of 97% and a specificity of 94%.

The question is that “do all hemodynamically unstable patients respond to a bolus of intravenous fluids—nearly half will not respond to intravenous bolus?” In a meta-analysis of 50 ICU studies and 2,260 patients, only half of patients were fluid responsive (at 95% confidence interval, 42–56%), with a sensitivity of 88%, and specificity of 92%.

This fact may manifest because it is also a fact that on the flatter right extreme of the Frank–Starling curve, the same

![Fig. 1](image1.png)

**Fig. 1** Fluid volume versus complication curve.

![Fig. 2](image2.png)

**Fig. 2** Daily fluid replenishment and occurrence of complications.
amount of the bolus fluid is not as effective in increasing the stroke volume as at the steeper part of the curve (Fig. 3).

Moreover, when PLR effects are assessed by changes in pulse pressure, the specificity of the PLR test remains acceptable, but its sensitivity is poor. Still PLR followed by measurement of CO or related parameters may be the most useful tests for predicting fluid responsiveness in hemodynamically unstable adults.4,6 Although the usefulness in assessment of respiratory variation in the vena cava requires confirmatory studies.4

Other commonly used CO measurement methods include indirect Fick methods, thermodilution (TD), Doppler ultrasound or echocardiography, partial carbon dioxide rebreathing, thoracic electrical bioimpedance, and magnetic resonance imaging. TD via the pulmonary artery catheter (PAC) is still considered to be the gold standard method in the clinical setting.7

Coming to the inherent technological difference, a device based on bioreactance (Starling, Baxter Inc. Deerfield, United States) works on phase shift or time delay (Fig. 4A), while bioimpedance works on the amplitude of the thoracic impedance. The flow of blood in the thorax introduces a time delay or “phase shift” in STARLING signal. These signal changes have been further correlated to the known TD CO of 65,000 patient samples in multiple clinical settings.

Unlike bioimpedance, bioreactance is not affected by the size of the patient, thoracic fluids (e.g., pleural effusion/pulmonary edema), or position of sensors. And here lies the advantage of a device based on bioreactance if utility and cost-effectiveness parameters are acceptable.
Method

We searched Scholar, MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) in the COCHRANE Library. The Medical Subject Headings terms “Fluid Management,” “Fluid responsiveness,” and “Non Invasive fluid management monitoring,” “Bio-Reactance,” “STARLING” were used. Additional studies were identified by review of the reference sections of all eligible studies. The aim of this review article is to bring together the evidences with bioreactance-based fluid management monitoring in critically ill patients.

STARLING

The STARLING system (Fig. 5) is equipped with four sensor pads. Each pad contains two sensors, the outer sensor is a transmitting electrode and the inner sensor is a receiving electrode. The sensors are applied around the heart on the chest or back (there is no need for exact positioning).

The STARLING monitor induces a 75 KHz AC current to the thorax via the outer sensors and receives the voltage via the inner sensors. It then measures the time delay/phase shift (as depicted in Fig. 4A) between the induced current and the received voltage continuously, thus building the STARLING signal. The final mechanistic flowchart is as shown in Fig. 6.

STARLING Validation Data with FloTrac, Esophageal Doppler Monitoring, and Thermodilution

CO measurements obtained from bioreactance-based monitoring and TD were simultaneously recorded minute-by-minute and compared in 110 patients. Bioreactance-based monitoring was evaluated for the accuracy, precision, responsiveness, and reliability for detecting CO changes. Total of 65,888 pairs of CO measurements were collected from 110 patients.8

In this study,7 the authors concluded that bioreactance-based fluid monitoring system had acceptable accuracy, precision, and responsiveness for CO monitoring in patients experiencing a wide range of circulatory situations. In yet another study,9 it was found that CO measured via bioreactance is precise and reliably measures CO at rest and changes in CO with vasodilator challenge in patients with pulmonary hypertension.

Bioreactance and Esophageal Doppler Monitor in Guiding Goal-Directed Fluid Therapy

Using McNemar’s p-value and 95% of agreement limit, a study10 has shown that the noninvasive CO monitoring performs similarly to the esophageal Doppler monitor in
guiding goal-directed fluid therapy, with no clinically significant differences in outcomes, and offers increased ease of use as well as fewer missing data points. Thus, the former may be a viable alternative monitor to guide.

This study was conducted in two consecutive phases. Phase I was conducted over an 8-month period, whereas phase II was conducted over a 6-month period immediately after phase I. Phase I and phase II patients had similar clinical outcomes, with no clinically significant differences in length of hospital stay, postoperative bowel function recovery, renal function, or other complications.

In phase I (50 patients), investigators used the esophageal Doppler monitor in guiding goal-directed fluid therapy while the bioreactance-based fluid monitoring was also connected and recorded hemodynamic variables. All decisions to administer fluid during phase I were based on measurements from the esophageal Doppler monitor, with no consideration given to the bioreactance-based fluid monitoring measurements.

In phase II (50 patients), goal-directed fluid therapy was guided by the bioreactance-based fluid monitoring measurements while hemodynamic variables were simultaneously recorded by the esophageal Doppler monitor. All decisions to administer fluid during phase II were based on measurements from the bioreactance-based fluid monitoring, with no consideration given to the esophageal Doppler monitor measurements.

There was reasonable correlation in baseline stroke volume. There also was agreement on fluid responsiveness between the monitors 66% of times and estimated to be at least 61% at 15 minutes with no significant systematic disagreement at any time point. In the study, no significant differences were found:

1. Between the bioreactance-based fluid monitoring and esophageal Doppler monitor in ability to assess fluid responsiveness as part of a goal-directed fluid therapy algorithm.
2. In length of hospital stay and postoperative recovery when goal-directed fluid therapy was guided by the bioreactance-based fluid monitoring or the esophageal Doppler monitor.

**Benefits of Noninvasive Fluid Response Monitoring in Indian Patients as Compared with Invasive (PAC) or Minimally Invasive (Vigileo, Transesophageal Echocardiography) (Consensus) Methods**

In a study of 29 patients, 12,099 simultaneous readings with three devices was conducted. TD-based continuous CO monitoring with PAC following cardiac surgery as gold standard was also done along with the two other devices, viz. minimally invasive FloTrac-Vigileo and a totally noninvasive CO monitoring.

CO values obtained simultaneously by the three systems were recorded continuously on a minute-by-minute basis. The new technology of noninvasive CO monitoring was considered as:

- Acceptably accurate when bias of measurement was less than 20%; acceptably precise when random error of measurements around the mean value were less than 20%; acceptably responsive when time delay and amplitude of change were at least equivalent to PAC determined continuous CO.

- Acceptably reliable when specificity and sensitivity in detecting simultaneous directional changes in CO was close to one.

**Kansas University Trial**

In this study, dynamic measure (stroke volume changes) used to guide fluid therapy in septic shock was associated with better clinical and economic outcomes. To determine whether stroke volume-guided fluid resuscitation in patients with severe sepsis and septic shock alters ICU fluid balance and secondary outcomes, this retrospective cohort study evaluated consecutive patients admitted to an ICU with the primary diagnosis of severe sepsis or septic shock. Cohorts were based on fluid resuscitation guided by changes in stroke volume or by usual care.

**Fluid Response Evaluation in Sepsis Hypotension and Shock (FRESH) Study**

In a prospective, multicenter, randomized clinical trial at 13 hospitals in the United States and United Kingdom, patients presented to emergency departments with sepsis that was associated with hypotension and anticipated ICU admission were studied. Intervention arm patients were assessed for fluid responsiveness before clinically driven fluid bolus or increase in vasopressors requirement.

The protocol included reassessment and therapy as indicated by the PLR result. The control arm received usual care. The primary clinical outcome was positive fluid balance at 72 hours or ICU discharge, whichever occurred first. Stroke volume-guided fluid and vasopressor management was used continuously during the intervention period (72 hours or ICU discharge, whichever occurred first).

An increase in stroke volume $\geq 10\%$ was considered fluid responsiveness. If the patient demonstrated fluid responsiveness, protocol prompts were provided to administer a crystalloid fluid bolus (500 mL) for persistent hypotension, with repeat PLRs after every fluid bolus.

If the patient was not fluid responsive, the initiation or up-titration of vasopressors was prompted with repeat PLR after significant escalation (an increase of 1 $\mu$g/kg/min norepinephrine). In this manner, the protocol allowed for the physiologic titration of both fluid and vasopressors to treat hypoperfusion.

The volume of administered fluids at 72 hours was significantly less in patients in the intervention arm than the usual care arm. Separation between arms for 72-hour fluid balance and total amount of administered intravenous fluids were maintained even when preenrollment fluid was included in the analysis.

Consistent with current guideline recommendations, patients received 2 to 3 L of intravenous fluids before randomization in both arms. These results indicate that PLR-guided protocol instructions during the first 72 hours of care accounted for the observed differences in fluid balance.
between arms. There was a reduced need for renal replacement therapy or invasive mechanical ventilation in the intervention arm.

On pre–post intervention assessment, a larger fluid difference (3.59 L) was reported between patients who were treated with PLR-guided strategy and usual care. Though authors found a smaller difference in the modified intent-to-treat analysis of the Fluid Response Evaluation in Sepsis Hypotension and Shock (FRESH) study, it can be due to more restrictive fluid management in the usual care arm.

However, the concordance in a lower risk for renal and respiratory failure between the two arms in the two studies suggests a consistent and strong clinical effect.

Additionally, studies of dynamic measure-guided fluid administration in surgical patients have reported comparable overall fluid administration between dynamic measure-guided treatment arms and usual care arms with greater preservation of renal and respiratory function in the intervention arm.

**STARLING: Implementing Noninvasive Fluid Management Monitoring in Indian Setting**

Because of the limitations of bioimpedance devices, newer methods of processing the impedance signal have been developed. Human thorax and thoracic content is reason for their resistance (R) and capacitance (C), which together create the thoracic impedance (Zo), when a current is passed through thorax. Phase shifts can occur only because of pulsatile flow. The overwhelming majority of thoracic pulsatile flow stems from the aorta. Therefore, the STARLING signal is correlated almost wholly with aortic flow. Furthermore, because the underlying level of thoracic fluid is relatively static, neither the underlying levels of thoracic fluids nor their changes induce any phase shifts and do not contribute to its signal.14

The CO as measured by bioreactance has been shown to have high correlation with that measured by TD and pulse contour analysis.15–19 Squara et al16 compared the STARLING system with PAC-derived CO in 110 patients after cardiac surgery. The reported bias was ±0.16 L/min; Limits of Agreement (LOA) on Bland and Altman representation of ±1.04 L/min with a relative error of 9%. The precision of the STARLING system was better than that of TD, with the device being able to track changes in CO accurately.

In a study of three ICUs (70 patients), Raval et al15 reported a bias of −0.09 L/min and an LOA of ±2.4 L/min, with the STARLING system closely tracking changes in the TD CO. Rich et al17 performed right-heart catheterization in 24 patients with pulmonary hypertension. Simultaneous CO measurements were performed using TD, STARLING, and the Fick methods at baseline and after adenosine vasodilator challenge. CO measured by the STARLING system was significantly more precise than that of TD. The adenosine challenge resulted in a similar mean increase in CO with each method. The accuracy of STARLING was assessed in hemodynamically unstable ICU patients and healthy volunteers after PLR and fluid challenges using carotid and brachial arterial Doppler ultrasound flow (mL/min) as the reference technique and

confirmed almost same as in a previous study19,20 where almost 100% concordance was found between fluid responsiveness as determined by carotid flow and the NICOM system.

Benomar et al21 showed that the NICOM system could predict fluid responsiveness accurately from changes in CO during PLR. As part of goal-directed perioperative therapy in patients undergoing major surgery, Waldron et al22 compared fluid responsiveness with an esophageal Doppler monitor and the NICOM system. Notwithstanding the limitations of esophageal Doppler monitoring (as discussed previously), there was a good agreement between these technologies.

STARLING system, personalized for fluid therapy:

1. Provides a dynamic assessment of fluid responsiveness—accurately, precisely, and 100% noninvasively. It supports individualized fluid therapy without requiring an invasive arterial or central line. It may reduce the risk of hospital-acquired infections and other complications. It has been independently validated against PAC, considered to be current gold standard in fluid monitoring therapy. Accuracy not affected by vasopressors or shock state and works in mechanically ventilated and spontaneously breathing patient. In Kansas trial also discussed previously, a retrospective analysis11 of 200 sepsis/septic shock patient has shown a cost–benefit of $14,498 per patient as result of reduction in ICU length of stay, acute dialysis, and mechanical ventilation. Although this was the study conducted in United States, its implication may extend to developing countries with significant health care burden like India. In view of high recurring costs associated with other invasive or minimally invasive hemodynamic monitoring modalities for the disposables, noninvasive disposable sensor pads used for STARLING can further reduce the recurring cost and economic burden of Indian patient.

STARLING system seems to be accurate, precise, and reasonably validated technology with over 500 patients in published clinical studies. Multiple clinical settings (ICU/operating room/emergency department/exercise laboratory/out of hospital) against all major technologies (Swan Ganz, Pulse Contour, Doppler, Fick) with over 100 peer-reviewed publications.

**Conclusion**

Overall, given the clinical apropos, economic benefits with STARLING-based stroke volume-guided fluid therapy, its impact on current clinical practice would mostly rely upon the advantage of noninvasiveness (and consequential benefits like less chances of procedural cost/pain/infection/hospital stay, etc.) and wide spectrum of patient applicability.

**Conflict of Interest**
The corresponding author is an Employee of Baxter India Pvt Ltd. No conflict for the remaining authors.

**References**

4 Bentzer P, Griesdale DE, Boyd J, MacLean K, Sirounis D, Ayas NT. Will this hemodynamically unstable patient respond to a bolus of intravenous fluids? JAMA 2016;316(12):1298–1309
18 Heerdt PM, Wagner CL, DeMais M, Savarese JJ. Noninvasive cardiac output monitoring with bioimpedance as an alternative to invasive instrumentation for preclinical drug evaluation in beagles. J Pharmacol Toxicol Methods 2011;64(02):111–118
20 Marik PE, Levetov A, Young A, et al. The use of NICOM (bioreactance) and carotid Doppler to determine volume responsiveness and blood flow redistribution following passive leg raising in hemodynamically unstable patients. Ann Crit Care 2012
22 Waldron NH, Miller TE, Nardiello J, et al. NICOM versus EDM guided goal directed fluid therapy in the perioperative period. Anesthesiology 2011;115:A680